Oxidized phospholipids and isoprostanes in atherosclerosis

Current Opinion in Lipidology

Volumn 9, Issue 5, 1998, Pages 441-448

  Witztum, Joseph L ^a   Berliner, Judith A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ISOPROSTANE; PHOSPHOLIPID; RECEPTOR; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CELL ACTIVATION; CELL TYPE; LIPID OXIDATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; DINOPROST; HUMANS; ISOMERISM; OXIDATION-REDUCTION; PHOSPHOLIPIDS;

ANIMALIA;

EID: 0031731850     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199810000-00008     Document Type: Review

References (62)

1. Steinberg D. LDL oxidation and its pathobiologic significance. J Biol Chem 272:20963-20966.
2. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Rad Biol Med 1995; 20:707-727.
3. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms, oxidation, inflammation and genetics. Circulation 1995; 91:2488-2496.
4. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al. The yin and yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 1997; 16:831-842.
5. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997; 17:2309-2315.
6. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997; 36:1-21.
7. 2 isoprostane isomers present in the liver. Forty-five isomers were identified that represent the three major classes. Random production is suggested.
8. 2 production by causing reduction of isoprostane endoperoxides.
9. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJD. A series of prostaglandin Fep2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990; 87:9383-9387.
10. Morrow JD, Roberts LJN. Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol 1994; 233:163-174.
11. 2 alpha in urine. Levels of compounds in urine of adults and children were compared and the effects of indomethacin determined. Indomethacin affected expression of both prostanes but there was greater inhibition of the former.
12. Patrignani P, Santini G, Panara MR, Sciulli MG, Greco A, Rotondo MT, et al. Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase-dependent F2-isoprostane formation. Br J Pharmacol 1996; 118:1285-1293.
13. Pratico D, FitzGerald GA. Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem 1996; 271:8919-8924.
14. 2 alpha correlated with cyclo-oxygenase-2 levels in mesangial cells. However, cyclo-oxygenase-2 inhibitors were much more effective in preventing production of prostaglandins than in inhibiting isoprostane production.
15. 2 alpha I in both blood and urine are unaffected by cyclo-oxygenase inhibitors.
16. 2 alpha but did supress dehydro thromboxane excretion.
17. 2 alpha compared with human umbilical vein, which had 11 pg/mg dry weight. Hydroxy linoleic acid was present at much higher levels, i.e. 0.5% of the total linoleic acid. No hydroxy linoleic acid was detected in human umbilical vein. It was concluded that, for the evaluation of lipid peroxidation in lesions, hydroxy linoleic acid is more suitable than isoprostane.
18. 2 alpha, staining of macrophages adjacent to the necrotic core, staining of smooth muscle cells and some extracellular staining was observed.
19. 2 alpha. Circumflex artery occlusion in a canine model did not increase urine levels. However, levels were significantly increased after reperfusion. At 30 min after lytic therapy, levels were threefold greater than pre-intervention levels but returned to normal at 24 h. Similar changes were seen in patients given thrombolytic therapy.
20. 2 alpha were increased twofold 6 h after angioplasty. After 24 h, levels had returned to those observed pre-intervention. Thrombolytic therapy also increased isoprostane production; however, there was only a slight effect of angiography.
21. Laskey RE, Mathews WR. Nitric oxide inhibits peroxynitrite-induced production of hydroxyeicosatetraenoic acids and F2-isoprostanes in phosphatidylcholine liposomes. Arch Biochem Biophys 1996; 330:193-198.
22. Natarajan R, Lanting L, Gonzales N, Nadler J. Formation of an F2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors. Am J Physiol 1996; 271:H159-H165.
23. Awad JA, Morrow JD, Hill KE, Roberts LJN, Burk RF. Detection and localization of lipid peroxidation in selenium- and vitamin E-deficient rats using F2-isoprostanes. J Nutr 1994; 124:810-816.
24. Hoffman SW, Moore S, Ellis EF. Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke 1997; 28:844-849.
25. Kromer BM, Tippins JR. Coronary artery constriction by the isoprostane 8-epi prostaglandin F2 alpha. Br J Pharmacol 1996; 119:1276-1280.
26. Leitinger N, Blazek I, Sinzinger H. The influence of isprostanes on ADP-induced platelet aggregation and cyclic AMP generation in human platelets. Thromb Res 1997; 86:337-342.
27. Takabashi K, Nammour TM, Fukunaga M, Ebert J, Morrow JD, Roberts LJD, et al. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. J Clin Invest 1992; 90:136-141.
28. 2 alpha.
29. 2 alpha stimulated calcium flux in cells co-transfected with either Gq or G11 but not with thromboxane receptor alone. Treatment of platelets with thromboxane antagonist desensitized iso F2 stimulation. The authors demonstrate that 8 iso PGF2 alpha acts on the thromboxane receptor by a Gq or G11 coupled mechanism.
30. 2 alpha. In contrast, rat smooth muscle cells responded to both agonist and 8-iso. Binding studies on SMC suggest two separate receptors.
31. 2α.
32. Prescott SM. Inflammatory actions of platelet-activating factor: Control by PAF acetylhydrolase. J Invest Allerg Clin Immun 1997; 7:416. This article reviews many of the biological actions of PAF.
33. Zimmerman GA, Elstad MR, Lorant DE, McIntyre TM, Prescott SM, Topham MK, et al. Platelet-activating factor (PAF): signaling and adhesion in cell-cell interactions. Adv Exper Med Biol 1996; 416:297-304.
34. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet activating factor acetylhydrolases. J Biol Chem 1997; 272:17895-17898. This is an excellent review of the PAF-AH enzymes, both extracellular and intracellular, and their role in hydrolysis of PAF and other similar oxidized phospholipids, such as those found in oxidized LDL.
35. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 1995; 96:2322-2330.
36. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95:774-782.
37. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96:2882-2891.
38. Watson AD, Leitinger N, Navab M, Faull KF, Hörkkö S, Witztum JL, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997; 272:13597-13607. This is a seminal paper that utilizes a variety of techniques to definitively identify two oxidized phospholipid products in MM-LDL responsible for induction of monocyte binding to endothelial cells, and to demonstrate the presence of these oxidized lipids in atherosclerotic lesions.
39. Leitinger N, Watson AD, Faull KF, Fogelman AM, Berliner JA. Monocyte binding to endothelial cells induced by oxidized phospholipids present in minimally oxidized low density lipoprotein is inhibited by a platelet activating factor receptor antagonist. Adv Exper Med Biol 1997; 433:379-382.
40. Sigari F, Lee C, Witztum JL, Heaven PD. Fibroblasts that overexpress 15-lipoxygenase generate bioactive and minimally modified LDL. Art Thromb Vasc Biol 1997; 17:3639-3645. The authors demonstrate that incubation of LDL with fibroblasts overexpressing 15-lipoxygenase generate MM-LDL. The MM-LDL are shown to have direct chemotactic activity for monocytes. Bioactivity resided in the lipid fraction, and was blocked by use of PAF-receptor antagonists. These studies suggest yet another proinflammatory activity of oxidized phospholipids is generated when LDL is mildly oxidized.
41. Lee C, Barnett J, Reaven PD. Liposomes enriched in oleic acid are less susceptible to oxidation and have less proinflammatory activity when exposed to oxidizing conditions. J Lipid Res 1988; 39:1239-1247.
42. Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Art Thromb Vasc Biol 1997; 17:680-687. These studies report novel biological effects of oxidized phospholipids that could influence ectopic calcification in the artery and possibly decrease calcification in bone, leading to osteoporosis.
43. Lehr HA, Weyrich AS, Saetzler RK, Jurek A, Arfors KE, Zimmerman GA, et al. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking [see comments]. J Clin Invest 1997; 99:2358-2364. A fascinating study demonstrating that within minutes of smoking a single cigarette, hamsters accumulate PAF-like lipids in blood and in-vivo activation of monocytes and platelets. These effects could be blocked by pretreatment with vitamin C. The study has important clinical implications.
44. Rota S, McWilliam NA, Baglin TP, Byrne CD. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: Modulation by oxidation and vitamin E. Blood 1998; 91:508-515. The authors demonstrate that oxidized phospholipids, as present in oxidized lipoproteins, provide an enhanced ability to support the assembly of prothrombinase complex and the enhanced generation of thrombin.
45. •].
46. •], reviews a variety of aspects of the chemistry and biology of oxidized phospholipids.
47. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994 to T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Met Clin Exp 1998; 47:177-181. An initial report suggesting that a specific mutation in the PAF-AH gene leading to inactivation confers an increased risk for coronary artery disease in Japanese men.
48. Romano M, Romano E, Bjorkerud S, Hurt-Camejo E. Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries. Art Thromb Vasc Biol 1998; 18:519-525.
49. Goyal J, Wang K, Liu M, Subbaiah PV. Novel function of lecithin-cholesterol acyltransferase. Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation. J Biol Chem 1997; 272:16231-16239. These novel studies report that LCAT can hydrolyze oxidized phospholipids independent of its cholesterol esterification activity. This suggests that LCAT might behave like PAF-AH, inactivating a variety of bioactive oxidized phospholipids.
50. Liu M, St Clair RW, Subbaiah PV. Impaired function of lecithin:cholesterol acyltransferase in atherosclerosis-susceptible White Carneau pigeons: possible effects on metabolism of oxidized phospholipids. J Lipid Res 1998; 39:245-254.
51. Mackness MI, Durrington PN. HDL. Its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115:243-253.
52. Banka CL. High density lipoprotein and lipoprotein oxidation. Curr Opin Lipidol 1996; 7:139-142.
53. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 15:101:1581-1590. An important paper that provides preliminary data on one important mechanism by which paraoxonase might influence lipoprotein oxidation via a peroxidase-like activity.
54. Itabe H, Sanaka T, Michishita I, Takano T. Pathophysiology of lipid peroxides and related free radicals. Yagik (editor). Tokyo: Japan Science Soc Press; 1998. pp. 13-24.
55. Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996; 98:800-814.
56. Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996; 98:815-825.
57. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T, Takano T. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 1994; 269:15274-15279.
58. Itabe H, Yamamoto H, Suzuki M, Kawai Y, Nakagawa Y, Suzuki A, et al. Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein. J Biol Chem 1996; 271:33208-33217.
59. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996; 37:45-53.
60. 2-GI or other proteins. This may mimic what happens when apoB is modified by oxidized lipids and the resulting lipid-apoB adducts are immunogenic.
61. Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palosuo T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91:23-27.
62. •] suggest that antiphospholipid antibodies should increase in situations of enhanced lipid peroxidation. In this study, in lupus patients who have increased titers of antiphospholipid antibodies, it was shown that there was a very strong correlation between the antibody titer and the urinary excretion of isoprostanes. This study supports the hypothesis that antiphospholipid antibodies may form in response to pro-oxidative conditions.